soul trial oral semaglutide cardiovascular outcomes 2025 results 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Trial Scorecard: SOUL

"What Acclaimed Author of "How Not to Die" Wants Us to Eat to Avoid an Early Death"

Future investigations should focus on identifying reliable predictive markers, developing more effective and individualized treatment strategies, and evaluating long-term outcomes in affected patients

Peptide 20, a GIPR/GLP-1R/GCGR triagonist (currently in phase 1 clinical trial) 17 with balanced potency at the three receptors, is evolved from a GLP-1R/GCGR dualagonist 18 through iterative sequence refinement and modification (Fig

If these patients have tried diet and exercise regimens and have not been successful, they may want to consider semaglutide or tirzepatide

When you're considering semaglutide for diabetes or weight management, understanding the prevalence of menstrual irregularities, including missed periods, is crucial

Namrata Hulawale, Allen Peng, Dr